Home Medicine Is it time to abandon the Nobel Prize?
Article Publicly Available

Is it time to abandon the Nobel Prize?

  • Clare Fiala and Eleftherios P. Diamandis EMAIL logo
Published/Copyright: February 19, 2018

This October, and every other October, a few hundred scientists will lose sleep, hoping to get a telephone call from the Swedish Academy, announcing they have reached what is considered the pinnacle of scientific achievement: they have won the Nobel Prize. Does this coveted prize benefit society and encourage innovation or does it create tension in the scientific community by only crediting at most three recipients? In this commentary, we make the case that it is time to abandon the Nobel Prize in favor of alternative recognitions which encompass the collaborative nature of modern science.

Is the Nobel Prize a major influential factor in scientific progress? We believe it is not. Nobel laureates are recognized for work done 10, 20 or even 30 years ago, when the investigator(s) did not know their research would have a Nobel Prize worthy impact. Consequently, the work would have been done anyway.

Winning a Nobel Prize is not the same as receiving any other award, and the sole beneficiary is the winner. Nobel laureates become instant celebrities; universally perceived as extremely smart and extraordinarily creative. They become “immortal” (whatever that means), are treated with the utmost respect and offered positions on prestigious boards in industry and government. They also secure a full-page obituary in both Nature and Science magazines.

While many Nobel laureates use their prestige to influence science policy and other high-level activities, it is questionable how big this impact really is. On numerous occasions, Nobel laureates have sailed in the wrong direction, by undertaking work in fields outside their Nobel-winning specialty they know little about. This hurts scientific progress as their fame makes their (incorrect) conclusions harder to discredit and encourages others to investigate dead end fields. Linus Pauling, winner of the Nobel Prize for Chemistry in 1954, began proclaiming the cancer- curing benefits of mega doses of vitamin C near the end of his career. Not only did this erroneous conclusion not do patients any good, years were wasted discrediting this theory. As we commented elsewhere, the Nobel Prize inflates laureates’ perception of their scientific prowess, leading to the damaging belief that their engagement in any project will lead to success, regardless of its relation to their prize winning contribution. Some Nobel laureates go on to develop “Hubris syndrome”, an affliction characterized by megalomania, narcissism and a craving for power which, as described by Owens and Davidson, could lead to dangerous behaviors [1]. We recently described a syndrome coined “Nobelitis” (affecting exclusively Nobel laureates!) which has many similarities to Hubris [2].

Is it reasonable to conclude that winning a Nobel is an individual’s single most important personal achievement? And does the process of winning the prize commensurates with our values as modern scientists? The Nobel rewards discoveries with a major impact on society, such as a new therapy, diagnostic procedure, methodology, etc. However, the reality is all these discoveries were going to be made anyway, probably with a little (1–10 year) delay. Scientists are obsessed by being the first to discover something, but in most cases their discoveries, or improved versions, are destined to also be made by others. For example, the new DNA sequencing techniques discovered by Sanger and Gilbert in the 1970s led to their 1980 Nobel Prize, but Gilbert’s method was never used widely and Sanger’s technique has already been replaced by new technologies which are thousands of times faster and cheaper. Moreover, discoveries are frequently made simultaneously in several laboratories. One wonders how important it is for a new technology to be discovered 1, 2 or 10 years earlier. Humans lived without smart phones for centuries. Could they have afforded living without cellphones for a few more years?

We are not disputing that making a discovery first has some value but overzealous efforts may have deleterious side effects. For example, this obsession can lead to unethical behaviors. Watson and Crick, winners of the 1962 Nobel Prize after discovering the double helix structure of DNA are thought to have stolen fundamental data from rival scientist Rosalind Franklin. There are numerous (known and unknown) examples, where scientists used unethical practices to publish something first, analogous to how doped athletes cheat in athletic competitions.

Some discoveries, especially in the area of molecular biology, are so powerful that those who find them believe that they can play God. For example, the revolutionary CRISPR technology led two co-investigators to write a book with the rather pompous title “A crack in creation” [3]. However, we should be aware that most of these discoveries represent “reverse engineering” of ingenious systems developed in bacteria, viruses and other organisms. The scientists who discovered them try to understand how these systems work and tweak their properties for new applications. If Nobel Prizes were to be awarded for inventions, then, the embryo developing in the womb would be a stellar contender for every physiology or medicine Nobel Prize that was ever given, or will be given.

A major problem with discoveries leading to Nobel Prizes is we often do not know precisely who made the discovery. In most cases it is not clear as the discoveries are the product of collective effort. In recent years, we have witnessed numerous disputes over who discovered first and who were the major players among principal investigators, postdoctoral fellows, graduate students and skilled technicians. While the Nobel committee recognizes one, two or a maximum of three individuals, discoveries, especially these days of big data and international collaboration, require collective, multidisciplinary effort. There are almost as many disputed cases as the Nobel Prizes themselves! (https://en.wikipedia.org/wiki/Nobel_Prize_controversies). Despite the way science is performed today has changed dramatically since Alfred Nobel established the awards in 1895, the maximum number of laureates is still three. We have not seen a concerted effort to pressure the Nobel committee to change the rules. The simplest way to achieve this is to let the committee know that if they do not change the rules, future laureates will not accept the awards. However, this is unlikely as most new laureates rush to give press conferences and reap the rewards of their celebrity as soon as the awards are announced, not caring about those who complain.

This commentary was inspired by the current discussion about the CRISPR technology which is (justifiably) now up for a Nobel Prize. One highly influential scientist published a perspective in 2016 describing “the heroes of CRISPR” [4]. This was taken by many as a preemptive strike, aiming to influence the Nobel committee as one of the co-discoverers comes from his institution. In what appeared to be a response, another co-discoverer, wrote a book with her own version of the events (https://en.wikipedia.org/wiki/Nobel_Prize_controversies). Would the other four or five “heroes” or designates, write their own versions too? This Nobel-prompted squabbling is not in line with scientific ethos, which is supposed to promote collegiality and collaboration. The scientists involved should show humility and generosity instead.

So, who is going to win the Nobel Prize for the discovery of the CRISPR technology or for other breakthroughs? It does not really matter. Those who co-discovered the system should be proud of being members of the team. We suggest to the co-discoverers, and all other Nobel-worthy discoverers, should not argue so much on who did what but humbly acknowledge the contributions of others who have helped science progress.

We conclude that it is likely better to abandon this highly prestigious award in favor of an alternative reward system which promotes collegiality, collaboration and humbleness.


Corresponding author: Eleftherios P. Diamandis, MD, PhD, FRCP(C), FRSC, Head of Clinical Biochemistry, Department of Clinical Biochemistry, University Health Network, 60 Murray St. Box 32, Floor 6, Rm L6-201, Toronto, ON, MST 3L9, Canada, Phone: +(416) 586-8443; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St. Box 32, Floor 6, Rm L6-201, Toronto, ON, MST 3L9, Canada; and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

References

1. Owen D, Davidson J. Hubris syndrome: an acquired personality disorder? A study of US Presidents and UK Prime Ministers over the last 100 years. Brain 2009;132:1396–406.10.1093/brain/awp008Search in Google Scholar PubMed

2. Diamandis EP. Nobelitis: a common disease among Nobel laureates? Clin Chem Lab Med 2013;51:1573–4.10.1515/cclm-2013-0273Search in Google Scholar PubMed

3. Doudna JA, Sternberg SH. A crack in creation. Boston: Houghton Mifflin Harcourt, 2017. (ISBN-10:0544716949).Search in Google Scholar

4. Lander ES. The heroes of CRISPR. Cell 2016;164:18–28.10.1016/j.cell.2015.12.041Search in Google Scholar PubMed

Published Online: 2018-02-19
Published in Print: 2018-07-26

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Procalcitonin for diagnosing and monitoring bacterial infections: for or against?
  4. Is it time to abandon the Nobel Prize?
  5. In Memoriam
  6. Norbert Tietz, 13th November 1926–23rd May 2018
  7. Reviews
  8. Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
  9. Telomere biology and age-related diseases
  10. Opinion Paper
  11. Procalcitonin-guided antibiotic therapy: an expert consensus
  12. Genetics and Molecular Diagnostics
  13. mRNA expression profile in peripheral blood mononuclear cells based on ADRB1 Ser49Gly and Arg389Gly polymorphisms in essential hypertension — a case-control pilot investigation in South Indian population
  14. General Clinical Chemistry and Laboratory Medicine
  15. External quality assessment schemes for glucose measurements in Germany: factors for successful participation, analytical performance and medical impact
  16. Long-term stability of glucose: glycolysis inhibitor vs. gel barrier tubes
  17. Observational studies on macroprolactin in a routine clinical laboratory
  18. Anti-streptavidin IgG antibody interference in anti-cyclic citrullinated peptide (CCP) IgG antibody assays is a rare but important cause of false-positive anti-CCP results
  19. Point-of-care creatinine testing for kidney function measurement prior to contrast-enhanced diagnostic imaging: evaluation of the performance of three systems for clinical utility
  20. Hematology and Coagulation
  21. Analytical performance of an automated volumetric flow cytometer for quantitation of T, B and natural killer lymphocytes
  22. Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity
  23. Reference Values and Biological Variations
  24. Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women
  25. Within-subject and between-subject biological variation estimates of 21 hematological parameters in 30 healthy subjects
  26. Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite® reagents
  27. Cancer Diagnostics
  28. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations
  29. Cardiovascular Diseases
  30. Clinical performance of a new point-of-care cardiac troponin I test
  31. Diabetes
  32. Testing for HbA1c, in addition to the oral glucose tolerance test, in screening for abnormal glucose regulation helps to reveal patients with early β-cell function impairment
  33. Effects of common hemoglobin variants on HbA1c measurements in China: results for α- and β-globin variants measured by six methods
  34. Infectious Diseases
  35. Serum procalcitonin concentration within 2 days postoperatively accurately predicts outcome after liver resection
  36. Predictive value of serum gelsolin and Gc globulin in sepsis – a pilot study
  37. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis
  38. Letter to the Editor
  39. Glucose and total protein: unacceptable interference on Jaffe creatinine assays in patients
  40. Interference of glucose and total protein on Jaffe-based creatinine methods: mind the covolume
  41. Interference of glucose and total protein on Jaffe based creatinine methods: mind the covolume – reply
  42. Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia
  43. Paraprotein interference in the diagnosis of hepatitis C infection
  44. Timeo apis mellifera and dona ferens: bee sting-induced Kounis syndrome
  45. Bacterial contamination of reusable venipuncture tourniquets in tertiary-care hospital
  46. Detection of EDTA-induced pseudo-leukopenia using automated hematology analyzer with VCS technology
  47. Early adjustment of antimicrobial therapy after PCR/electrospray ionization mass spectrometry-based pathogen detection in critically ill patients with suspected sepsis
  48. Thromboelastometry reveals similar hemostatic properties of purified fibrinogen and a mixture of purified cryoprecipitate protein components
  49. Bicarbonate interference on cobas 6000 c501 chloride ion-selective electrodes
Downloaded on 24.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2018-0027/html
Scroll to top button